The Dana-Farber Cancer Institute is home to leading investigators who have made key discoveries regarding the immune response to cancer. PICI scientists at Dana-Farber are working collaboratively together and within the PICI network to better understand the tumor immune microenvironment across cancer types. The intent is to translate these basic discoveries to the clinic as impactful immunotherapies to fight cancer and improve patient outcomes. PICI at Dana-Farber Cancer Institute promotes innovation and collaboration in order to advance our understanding of the immune response to cancer and develop novel immunotherapy strategies for the benefit of our patients. Areas of scientific interest: Discovering novel therapeutic targets and their mechanism of action Investigating the tumor immune microenvironment to better understand response, resistance and toxicity of immunotherapy Developing next generation cellular therapies Advancing vaccines as a platform for combination therapies Elizabeth A. Mittendorf, MD, PhD | Co-Director F. Stephen Hodi, MD | Co-Director Kai W. Wucherpfennig, MD, PhD | Co-Director All Investigators Related Press Release PICI, JDRF and Helmsley Trust Form Research Initiative Cancer Research Heroes, Research Update Personalized Cancer Vaccines to Conquer Cancer Research Update Personalized cancer neoantigen vaccines show success in two small studies Announcement, From Bench to Fireside From NK Cell Biology to a Career in Breakthrough Science with Lewis Lanier, PhD Announcement, From Bench to Fireside Introducing: From Bench to Fireside Announcement PICI Network at #SITC23 Announcement, Our Impact PICI Network Members at #AACRtii23 Announcement PICI Welcomes New UCSF Center Director Announcement New Staff Members Join PICI
Announcement, From Bench to Fireside From NK Cell Biology to a Career in Breakthrough Science with Lewis Lanier, PhD